Breast Cancer

Disease State Hub

Research Summaries

Research Summary

woman lying in hospital bed + cancer + hospice care

Research Summary

Top US Cancer Centers Often Diverge From USPSTF Cancer Screening Guidance, Cross-Sectional Study Finds

03/26/2015

Ashton L. Stahl

Physicians reviewing patient-facing screening guidance from major cancer centers may encounter recommendations that do not fully align with USPSTF standards. In a cross-sectional analysis, investigators...

03/26/2015

Breast cancer

Gene Deficiency Ups Triple-Negative Breast Cancer Risk 35-Fold

02/02/2015

New research has linked a deficiency in the gene beclin 1, which controls autophagy, to an increased risk in developing triple-negative breast cancer.

02/02/2015

Research Summaries

FDA Approval

FDA Approval

FDA Grants Accelerated Approval to Camizestrant Combination for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Anthony Calabro, MA

The FDA approval addresses acquired endocrine resistance by allowing eligible patients with HR-positive, HER2-negative advanced breast cancer to switch to camizestrant when an ESR1 mutation is detected in...

09/18/2026

Research Summary

Research Summary

Long-Term Hormone Therapy Shows Regimen-Specific Risks, Benefits in Menopausal Women

09/15/2026

Anthony Calabro, MA

An updated systematic review of randomized, placebo-controlled trials found that long-term combined and estrogen-only hormone therapy may have different risk-benefit profiles for stroke, breast cancer,...

09/15/2026

Conference Coverage

Conference Coverage

PUPC Recap—Evidence-Based Cancer Screening in Primary Care: Breast, Cervical, and Colorectal Updates for Clinicians

08/19/2026

Ashton L. Stahl

In their Practical Updates in Primary Care session, Jeanne M. Ferrante, MD, MPH, and Nell Maloney Patel, MD, FACS, FASCRS, discussed evidence-based cancer screening updates for primary care, with emphasis...

08/19/2026

Timelines

Notable FDA Approvals in July

07/27/2026

July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

07/27/2026

FDA Approval

FDA Approval

FDA Approves Gedatolisib After Endocrine Therapy Progression in Advanced Breast Cancer

07/17/2026

Anthony Calabro, MA

The FDA approved gedatolisib with fulvestrant, with or without palbociclib, for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected after...

07/17/2026

October 2026

Current Issue

October 2026